Updated safety & antileukemic activity data of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in treatment-naive patients with acute myeloid leukemia unfit for intensive chemotherapy

Disease State: Acute myeloid leukemia

BGB-11417-103 Trial

BGB-11417-103 (NCT04771130) is a Phase 1b/2, open-label, dose-finding, and expansion study of sonrotoclax in patients with myeloid malignancies.

Reading
28 May 2025

BGB-11417-103 (NCT04771130) is a Phase 1b/2, open-label, dose-finding, and expansion study of sonrotoclax in patients with myeloid malignancies.

Reading
6 Dec 2024

Sonrotoclax is an investigational potent and selective inhibitor of BCL2.

6 Dec 2024